Teva Innovative Medicine & Biosimilar Pipeline

By development stage – as of November 1, 2023

Technology Platforms:

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Under Regulatory Review

Biosimilar to Humira®
(adalimumab) 03

Biosimilar to Stelara® (Ustekinumab) 03

Digihaler®
(budesonide and formoterol
fumarate dihydrate) 02
(EU)
Asthma & COPD

Phase 3

Biosimilar to Eylea® (aflibercept) 03

Biosimilar to Prolia® & Xgeva® (denosumab)

Biosimilar to Xolair® (omalizumab)

Olanzapine LAI
(TEV-'749)
Schizophrenia

SABA/ICS
(TEV-'248)
Asthma

Biosimilar to Simponi® (golimumab) 03

Phase 2

Anti-TL1A
(TEV-'574)
Ulcerative Colitis, Crohn’s Disease

Emrusolmin
(TEV- '286) 01
Multiple System Atrophy

Phase 1

TEV-'408
Gastrointestinal

TEV-'192
Neuroscience

Pre-clinical

TEV-'6000
Neuroscience

TEV-'278
Oncology

TEV-'279
Neuroscience

TEV-'287 01
Neuroscience

TEV-'285

TEV-'191

TEV-'261

TEV-'284 03

TEV-'289

TEV-'288
Neuroscience

TEV-'292 03

TEV-'294 03

TEV-'295 03

TEV-'296 03

Novel Biologics
Small Molecules
Digital Respiratory
Biosimilars

Download a PDF version of Teva Innovative Medicine and Biosimilar Pipeline

Download PDF

Teva innovative medicine & biosimilar pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.

Pipeline is current as of November 1, 2023.

  1. Back to contents.

    In collaboration with MODAG.

  2. Back to contents.

    Approved and launched in UK, under review EU.

  3. Back to contents.

    In collaboration with Alvotech for the U.S. market.